Clinical guideline for the management of Gallbladder Polyps

This guidance does not override the individual responsibility of health professionals to make appropriate decisions according to the circumstances of the individual patient in consultation with the patient and/or carer. Health care professionals must be prepared to justify any deviation from this guidance.

Introduction

This guideline is a decision making tool using best current guidance for the management of incidentally or otherwise identified gallbladder polyps.

This guideline is for use by the following staff groups:

All clinicians and Sonographers.

Lead Clinician(s)

Dr A. Nilak and Dr S. Cader  Consultant Radiologist

Mr M Wadley  Consultant Upper GI surgeon

Approved by Radiology Directorate Governance meeting  8th November 2023

Review Date

This is the most current version and should be used until a revised document is in place:

8th November 2026

Key amendments to this guideline

<table>
<thead>
<tr>
<th>Date</th>
<th>Amendment</th>
<th>Approved by:</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.10.20</td>
<td>Reviewed and updated into clinical guideline template</td>
<td>Radiology directorate governance meeting</td>
</tr>
<tr>
<td>8th Nov 23</td>
<td>Updated guidance on timescales and management based on multiagency review</td>
<td>Radiology directorate governance meeting</td>
</tr>
</tbody>
</table>
Clinical guideline for the management of Gallbladder Polyps

Introduction

The management of incidentally detected gallbladder polyps on radiological examinations is contentious. The incidental radiological finding of a gallbladder polyp can therefore be problematic for the radiologist and the clinician who referred the patient for the radiological examination. To address this, a joint guideline was created by the European Society of Gastrointestinal and Abdominal Radiology (ESGAR), European Association for Endoscopic Surgery and other Interventional Techniques (EAES), International Society of Digestive Surgery – European Federation (EFISDS) and European Society of Gastrointestinal Endoscopy (ESGE).

In 2022, joint updated guidelines between ESGRA, EAES, EFIDS and ESGE was produced and published – these updates are reflected in the guidance below.

Key Points

- Management of gallbladder polyps is contentious. Ultrasound is the primary method of assessment, but EUS and CEUS also have some use in specialist centres.
- Cholecystectomy is recommended for gallbladder polyps >10 mm
- Cholecystectomy is recommended for gallbladder polyps measuring 6-9 mm in patients with one or more associated risk factors.
- If the patient has either no risk factors for malignancy and a gallbladder polypoid lesion of 6–9 mm, or risk factors for malignancy and a gallbladder polypoid lesion 5 mm or less, follow-up ultrasound of the gallbladder is recommended at 6 months, 1 year and 2 years. Follow-up should be discontinued after 2 years in the absence of growth. Moderate strength recommendation, moderate-quality evidence.
- If the patient has no risk factors for malignancy, and a gallbladder polypoid lesion of 5 mm or less, follow-up is not required. Strong recommendation, moderate-quality evidence.
- If during follow-up the gallbladder polypoid lesion grows to 10 mm, then cholecystectomy is advised. If the polypoid lesion grows by 2 mm or more within the 2-year follow-up period, then the current size of the polypoid lesion should be considered along with patient risk factors. Multidisciplinary discussion may be employed to decide whether continuation of monitoring, or cholecystectomy, is necessary. Moderate strength recommendation, moderate-quality evidence.
- If during follow-up the gallbladder polypoid lesion disappears, then monitoring can be discontinued.
It is the responsibility of every individual to ensure this is the latest version as published on the Trust Intranet.

Management and Follow-up of Gallbladder Polyps
(detected on transabdominal ultrasound; excluding definite pseudo-polyp)

≥ 10 mm

Cholecystectomy is suggested if no alternative cause for the patient's symptoms is demonstrated and the patient is fit for, and accepts, surgery. The patient should be counselled regarding the benefit of cholecystectomy versus the risk of persistent symptoms.

< 10 mm

Cholecystectomy is recommended providing the patient is fit for, and accepts, surgery. Multidisciplinary discussion may be employed to assess perceived individual risk of malignancy.

Does the patient have symptoms that are attributable to the gallbladder?

Yes

No

Does patient have one or more risk factors for malignancy? *

- Age > 60 years
- Primary sclerosing cholangitis (PSC)
- Asian ethnicity
- Sessile polyoid lesion (incl. focal gallbladder wall thickening > 4 mm)

Polyp ≤ 5 mm:
Follow-up not required

Polyp 6-9 mm:
Follow-up ultrasound * of the gallbladder is recommended at 6 months, 1 year and 2 years. Follow-up should be discontinued after 2 years in the absence of growth.

Notes:
* If cholecystectomy is not deemed appropriate, then follow-up is recommended as per guidelines
* If a patient has a risk factor, the presence of a solitary polyp strengthens the evidence that malignant potential exists, and cholecystectomy should be considered
* Concerning polyp growth:
If during follow-up the gallbladder polyoid lesion reaches 10 mm cholecystectomy is advised.
If the polyoid lesion grows by 2 mm or more within the 2-year follow-up, its current size should be considered along with patient risk factors. Multidisciplinary discussion may be employed to decide whether continuation of monitoring, or cholecystectomy, is necessary.
If polyoid lesion disappears then monitoring can be discontinued.

Fig. 1 Management algorithm
Ultrasound Dept Information

If a GB polyp is identified:

1. Review previous ultrasound examinations to determine if this a new finding.
2. If this a follow up scan – please state interval in report and make direct comparison to the previous scan.
3. Report is to include a description of polyp and include maximum size diameter and location.
4. GB polyps are to be managed by primary care until the guidance suggests referral to specialist.
5. All reports for GB polyps (new and follow up) are to include link to this clinical guideline document on the treatment pathways page. (Short code polyp ALT+P)
6. Primary care is to make follow up scan requests as suggested in the flowchart above. These will only be accepted up to 1 year in advance.
7. During vetting if a follow up scan is requested, these must be placed on the planned list at the appropriate interval from the previous scan date.

- “Polypoid lesions of the Gallbladder” refers to any elevated lesion of the mucosal surface of the gallbladder wall
- Cholesterol polyps account for the vast majority of all polyps (approximately 62%) (3)
- Adenomas, which account for approximately 6%, have malignant potential. (3)
- On the basis of their morphologic features, gallbladder polyps are stratified into three categories: extremely low risk, low risk, and indeterminate risk. (2)
- Extremely low risk polyps are pedunculated with a “ball-on-the-wall” configuration or thin stalk; low risk polyps are pedunculated with a thick or wide stalk or sessile configuration; indeterminate risk polyps have focal wall thickening adjacent to the polyp. (2)
REFERENCES


It is the responsibility of every individual to ensure this is the latest version as published on the Trust Intranet.

**Contribution List**

This key document has been circulated to the following individuals for consultation:

<table>
<thead>
<tr>
<th>Designation</th>
</tr>
</thead>
<tbody>
<tr>
<td>US lead sonographers</td>
</tr>
<tr>
<td>US Lead Radiologist</td>
</tr>
<tr>
<td>Upper GI Radiologist</td>
</tr>
<tr>
<td>Upper GI Surgeon / Clinical Lead.</td>
</tr>
</tbody>
</table>

This key document has been circulated to the chair(s) of the following committee’s / groups for comments:

<table>
<thead>
<tr>
<th>Committee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Radiology directorate governance meeting group</td>
</tr>
</tbody>
</table>
Supporting Document 1 - Equality Impact Assessment Tool

To be completed by the key document author and included as an appendix to key document when submitted to the appropriate committee for consideration and approval.

Please complete assessment form on next page;
Herefordshire & Worcestershire STP - Equality Impact Assessment (EIA) Form
Please read EIA guidelines when completing this form

**Section 1 - Name of Organisation**

<table>
<thead>
<tr>
<th>Herefordshire &amp; Worcestershire STP</th>
<th>Herefordshire Council</th>
<th>Herefordshire CCG</th>
</tr>
</thead>
<tbody>
<tr>
<td>Worcestershire Acute Hospitals NHS Trust</td>
<td>Worcestershire County Council</td>
<td>Worcestershire CCGs</td>
</tr>
<tr>
<td>Worcestershire Health and Care NHS Trust</td>
<td>X</td>
<td>Other (please state)</td>
</tr>
</tbody>
</table>

**Name of Lead for Activity**

**Details of individuals completing this assessment**

<table>
<thead>
<tr>
<th>Name</th>
<th>Job title</th>
<th>e-mail contact</th>
</tr>
</thead>
<tbody>
<tr>
<td>Julia Rhodes</td>
<td>Q/G lead radiographer</td>
<td><a href="mailto:Julia.rhodes1@nhs.net">Julia.rhodes1@nhs.net</a></td>
</tr>
</tbody>
</table>

**Date assessment completed**

15.10.20

**Section 2**

**Activity being assessed** (e.g. policy/procedure, document, service redesign, policy, strategy etc.)

<table>
<thead>
<tr>
<th>Title: Guideline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical guideline for the management of Gallbladder Polyps</td>
</tr>
</tbody>
</table>

**What is the aim, purpose and/or intended outcomes of this Activity?**

Clinical guideline

**Who will be affected by the development & implementation of this activity?**

- Service User
- Patient
- Carers
- Visitors
- Staff
- Communities
- Other

**Is this:**

- Review of an existing activity
- New activity
- Planning to withdraw or reduce a service, activity or presence?
It is the responsibility of every individual to ensure this is the latest version as published on the Trust Intranet.

Management and follow-up of gallbladder polyps, Eur Radiol (2017) 27:3856-3866

What information and evidence have you reviewed to help inform this assessment? (Please name sources, eg demographic information for patients / services / staff groups affected, complaints etc.)

Summary of engagement or consultation undertaken (e.g. who and how have you engaged with, or why do you believe this is not required)

Summary of relevant findings

Section 3
Please consider the potential impact of this activity (during development & implementation) on each of the equality groups outlined below. Please tick one or more impact box below for each Equality Group and explain your rationale. Please note it is possible for the potential impact to be both positive and negative within the same equality group and this should be recorded. Remember to consider the impact on e.g. staff, public, patients, carers etc. in these equality groups.

<table>
<thead>
<tr>
<th>Equality Group</th>
<th>Potential positive impact</th>
<th>Potential neutral impact</th>
<th>Potential negative impact</th>
<th>Please explain your reasons for any potential positive, neutral or negative impact identified</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>x</td>
<td></td>
<td></td>
<td>Best current practice</td>
</tr>
<tr>
<td>Disability</td>
<td>x</td>
<td></td>
<td></td>
<td>Best current practice</td>
</tr>
<tr>
<td>Gender Reassignment</td>
<td>x</td>
<td></td>
<td></td>
<td>Best current practice</td>
</tr>
<tr>
<td>Marriage &amp; Civil Partnerships</td>
<td>x</td>
<td></td>
<td></td>
<td>Best current practice</td>
</tr>
<tr>
<td>Pregnancy &amp; Maternity</td>
<td>x</td>
<td></td>
<td></td>
<td>Best current practice</td>
</tr>
<tr>
<td>Race including Traveling Communities</td>
<td>x</td>
<td></td>
<td></td>
<td>Best current practice</td>
</tr>
<tr>
<td>Religion &amp; Belief</td>
<td>x</td>
<td></td>
<td></td>
<td>Best current practice</td>
</tr>
<tr>
<td>Sex</td>
<td>x</td>
<td></td>
<td></td>
<td>Best current practice</td>
</tr>
<tr>
<td>Sexual Orientation</td>
<td>x</td>
<td></td>
<td></td>
<td>Best current practice</td>
</tr>
<tr>
<td>Other Vulnerable and Disadvantaged Groups (e.g. carers;</td>
<td>x</td>
<td></td>
<td></td>
<td>Best current practice</td>
</tr>
</tbody>
</table>
**Section 4**

**What actions will you take to mitigate any potential negative impacts?**

<table>
<thead>
<tr>
<th>Risk identified</th>
<th>Actions required to reduce / eliminate negative impact</th>
<th>Who will lead on the action?</th>
<th>Timeframe</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**How will you monitor these actions?**

| N/A |   |   |   |

**When will you review this EIA?**

| N/A |   |   |   |

---

**Section 5** - Please read and agree to the following Equality Statement

**1. Equality Statement**

1.1. All public bodies have a statutory duty under the Equality Act 2010 to set out arrangements to assess and consult on how their policies and functions impact on the 9 protected characteristics: Age; Disability; Gender Reassignment; Marriage & Civil Partnership; Pregnancy & Maternity; Race; Religion & Belief; Sex; Sexual Orientation

1.2. Our Organisations will challenge discrimination, promote equality, respect human rights, and aims to design and implement services, policies and measures that meet the diverse needs of our service, and population, ensuring that none are placed at a disadvantage over others.

1.3. All staff are expected to deliver services and provide services and care in a manner which respects the individuality of service users, patients, carer’s etc, and as such treat them and members of the workforce respectfully, paying due regard to the 9 protected characteristics.

---

**Clinical Guideline for the Management of Gallbladder Polyps**

**WAHT-KD-024** Page 10 of 12 Version 2
It is the responsibility of every individual to ensure this is the latest version as published on the Trust Intranet.

| Signature of person completing EIA |  
| Date signed | 19.10.20 |
| Comments: |  
| Signature of person the Leader Person for this activity |  
| Date signed |  
| Comments: |  

---

Clinical Guideline for the Management of Gallbladder Polyps

**WAHT-KD-024**

Page 11 of 12

Version 2
Supporting Document 2 – Financial Impact Assessment

To be completed by the key document author and attached to key document when submitted to the appropriate committee for consideration and approval.

<table>
<thead>
<tr>
<th>Title of document:</th>
<th>Yes/No</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Does the implementation of this document require any additional Capital resources</td>
<td>No</td>
</tr>
<tr>
<td>2. Does the implementation of this document require additional revenue</td>
<td>No</td>
</tr>
<tr>
<td>3. Does the implementation of this document require additional manpower</td>
<td>No</td>
</tr>
<tr>
<td>4. Does the implementation of this document release any manpower costs through a change in practice</td>
<td>No</td>
</tr>
<tr>
<td>5. Are there additional staff training costs associated with implementing this document which cannot be delivered through current training programmes or allocated training times for staff</td>
<td>No</td>
</tr>
</tbody>
</table>

Other comments:

If the response to any of the above is yes, please complete a business case and which is signed by your Finance Manager and Directorate Manager for consideration by the Accountable Director before progressing to the relevant committee for approval.